Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Dianthus Therapeutics (DNTH) EBIT (2017 - 2025)

Dianthus Therapeutics (DNTH) has 7 years of EBIT data on record, last reported at -$40.3 million in Q3 2025.

  • For Q3 2025, EBIT fell 34.74% year-over-year to -$40.3 million; the TTM value through Sep 2025 reached -$140.3 million, down 69.24%, while the annual FY2024 figure was -$101.9 million, 111.45% down from the prior year.
  • EBIT reached -$40.3 million in Q3 2025 per DNTH's latest filing, down from -$34.9 million in the prior quarter.
  • Across five years, EBIT topped out at -$7.7 million in Q1 2023 and bottomed at -$40.3 million in Q3 2025.
  • Average EBIT over 4 years is -$21.9 million, with a median of -$18.1 million recorded in 2022.
  • Peak YoY movement for EBIT: skyrocketed 67.76% in 2023, then plummeted 146.34% in 2024.
  • A 4-year view of EBIT shows it stood at -$10.7 million in 2022, then dropped by 21.16% to -$13.0 million in 2023, then tumbled by 146.34% to -$31.9 million in 2024, then dropped by 26.23% to -$40.3 million in 2025.
  • Per Business Quant database, its latest 3 readings for EBIT were -$40.3 million in Q3 2025, -$34.9 million in Q2 2025, and -$33.2 million in Q1 2025.